Granisetron versus tropisetron for prophylaxis of acute chemotherapy-induced emesis: A pooled analysis

Karin Jordan, Axel Hinke, Axel F Grothey, Hans Joachim Schmoll

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

This analysis compares the antiemetic efficacy of the 5-HT 3-receptor antagonists granisetron and tropisetron in acute chemotherapy-induced nausea and vomiting (CINV). All published randomized studies comparing granisetron with tropisetron in conventionally-dosed, emetogenic chemotherapy are included in this pooled analysis. The target criterion for antiemetic success was 'acute complete response' (complete absence of vomiting in the 24 h after the start of chemotherapy) and the rate of successful treatment reported as 'response rate' (acute complete response rate per patient). Twelve studies were used comprising 810 patients. Comparison between granisetron and tropisetron in patients receiving cisplatin-based therapy showed superiority of granisetron (odds ratio above 1.0) in six out of seven studies. However, this difference did not reach statistical significance. In patients receiving noncisplatin-based therapies, four out of five studies showed an advantage of granisetron over tropisetron with one study showing a significant advantage. Pooled analysis of all studies demonstrated a significant overall advantage for granisetron over tropisetron (p=0.042). This is supported by the individual studies: overall, ten out of the 12 studies analyzed showed an advantage for granisetron, with a 6.4% difference in response rate. This advantage was more pronounced in noncisplatin-based therapy (7.3%), whereas in cisplatin-based therapy, the difference was 5.4%. The overall results of this pooled analysis of cisplatin and noncisplatin-based studies suggest that granisetron has a marginal but clinically potentially relevant statistically significant advantage in efficacy over tropisetron for the control of acute CINV.

Original languageEnglish (US)
Pages (from-to)26-31
Number of pages6
JournalSupportive Care in Cancer
Volume13
Issue number1
DOIs
StatePublished - Jan 2005
Externally publishedYes

Fingerprint

tropisetron
Granisetron
Vomiting
Drug Therapy
Cisplatin
Antiemetics
Nausea
Therapeutics
Serotonin Receptors

Keywords

  • Antiemetic
  • CINV
  • Efficacy
  • Granisetron
  • Tropisetron

ASJC Scopus subject areas

  • Oncology
  • Nursing(all)

Cite this

Granisetron versus tropisetron for prophylaxis of acute chemotherapy-induced emesis : A pooled analysis. / Jordan, Karin; Hinke, Axel; Grothey, Axel F; Schmoll, Hans Joachim.

In: Supportive Care in Cancer, Vol. 13, No. 1, 01.2005, p. 26-31.

Research output: Contribution to journalArticle

Jordan, Karin ; Hinke, Axel ; Grothey, Axel F ; Schmoll, Hans Joachim. / Granisetron versus tropisetron for prophylaxis of acute chemotherapy-induced emesis : A pooled analysis. In: Supportive Care in Cancer. 2005 ; Vol. 13, No. 1. pp. 26-31.
@article{ccabb21132a848448d76e3696638cea6,
title = "Granisetron versus tropisetron for prophylaxis of acute chemotherapy-induced emesis: A pooled analysis",
abstract = "This analysis compares the antiemetic efficacy of the 5-HT 3-receptor antagonists granisetron and tropisetron in acute chemotherapy-induced nausea and vomiting (CINV). All published randomized studies comparing granisetron with tropisetron in conventionally-dosed, emetogenic chemotherapy are included in this pooled analysis. The target criterion for antiemetic success was 'acute complete response' (complete absence of vomiting in the 24 h after the start of chemotherapy) and the rate of successful treatment reported as 'response rate' (acute complete response rate per patient). Twelve studies were used comprising 810 patients. Comparison between granisetron and tropisetron in patients receiving cisplatin-based therapy showed superiority of granisetron (odds ratio above 1.0) in six out of seven studies. However, this difference did not reach statistical significance. In patients receiving noncisplatin-based therapies, four out of five studies showed an advantage of granisetron over tropisetron with one study showing a significant advantage. Pooled analysis of all studies demonstrated a significant overall advantage for granisetron over tropisetron (p=0.042). This is supported by the individual studies: overall, ten out of the 12 studies analyzed showed an advantage for granisetron, with a 6.4{\%} difference in response rate. This advantage was more pronounced in noncisplatin-based therapy (7.3{\%}), whereas in cisplatin-based therapy, the difference was 5.4{\%}. The overall results of this pooled analysis of cisplatin and noncisplatin-based studies suggest that granisetron has a marginal but clinically potentially relevant statistically significant advantage in efficacy over tropisetron for the control of acute CINV.",
keywords = "Antiemetic, CINV, Efficacy, Granisetron, Tropisetron",
author = "Karin Jordan and Axel Hinke and Grothey, {Axel F} and Schmoll, {Hans Joachim}",
year = "2005",
month = "1",
doi = "10.1007/s00520-004-0672-8",
language = "English (US)",
volume = "13",
pages = "26--31",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Granisetron versus tropisetron for prophylaxis of acute chemotherapy-induced emesis

T2 - A pooled analysis

AU - Jordan, Karin

AU - Hinke, Axel

AU - Grothey, Axel F

AU - Schmoll, Hans Joachim

PY - 2005/1

Y1 - 2005/1

N2 - This analysis compares the antiemetic efficacy of the 5-HT 3-receptor antagonists granisetron and tropisetron in acute chemotherapy-induced nausea and vomiting (CINV). All published randomized studies comparing granisetron with tropisetron in conventionally-dosed, emetogenic chemotherapy are included in this pooled analysis. The target criterion for antiemetic success was 'acute complete response' (complete absence of vomiting in the 24 h after the start of chemotherapy) and the rate of successful treatment reported as 'response rate' (acute complete response rate per patient). Twelve studies were used comprising 810 patients. Comparison between granisetron and tropisetron in patients receiving cisplatin-based therapy showed superiority of granisetron (odds ratio above 1.0) in six out of seven studies. However, this difference did not reach statistical significance. In patients receiving noncisplatin-based therapies, four out of five studies showed an advantage of granisetron over tropisetron with one study showing a significant advantage. Pooled analysis of all studies demonstrated a significant overall advantage for granisetron over tropisetron (p=0.042). This is supported by the individual studies: overall, ten out of the 12 studies analyzed showed an advantage for granisetron, with a 6.4% difference in response rate. This advantage was more pronounced in noncisplatin-based therapy (7.3%), whereas in cisplatin-based therapy, the difference was 5.4%. The overall results of this pooled analysis of cisplatin and noncisplatin-based studies suggest that granisetron has a marginal but clinically potentially relevant statistically significant advantage in efficacy over tropisetron for the control of acute CINV.

AB - This analysis compares the antiemetic efficacy of the 5-HT 3-receptor antagonists granisetron and tropisetron in acute chemotherapy-induced nausea and vomiting (CINV). All published randomized studies comparing granisetron with tropisetron in conventionally-dosed, emetogenic chemotherapy are included in this pooled analysis. The target criterion for antiemetic success was 'acute complete response' (complete absence of vomiting in the 24 h after the start of chemotherapy) and the rate of successful treatment reported as 'response rate' (acute complete response rate per patient). Twelve studies were used comprising 810 patients. Comparison between granisetron and tropisetron in patients receiving cisplatin-based therapy showed superiority of granisetron (odds ratio above 1.0) in six out of seven studies. However, this difference did not reach statistical significance. In patients receiving noncisplatin-based therapies, four out of five studies showed an advantage of granisetron over tropisetron with one study showing a significant advantage. Pooled analysis of all studies demonstrated a significant overall advantage for granisetron over tropisetron (p=0.042). This is supported by the individual studies: overall, ten out of the 12 studies analyzed showed an advantage for granisetron, with a 6.4% difference in response rate. This advantage was more pronounced in noncisplatin-based therapy (7.3%), whereas in cisplatin-based therapy, the difference was 5.4%. The overall results of this pooled analysis of cisplatin and noncisplatin-based studies suggest that granisetron has a marginal but clinically potentially relevant statistically significant advantage in efficacy over tropisetron for the control of acute CINV.

KW - Antiemetic

KW - CINV

KW - Efficacy

KW - Granisetron

KW - Tropisetron

UR - http://www.scopus.com/inward/record.url?scp=13244249758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13244249758&partnerID=8YFLogxK

U2 - 10.1007/s00520-004-0672-8

DO - 10.1007/s00520-004-0672-8

M3 - Article

C2 - 15668744

AN - SCOPUS:13244249758

VL - 13

SP - 26

EP - 31

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 1

ER -